With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...